Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Gastric Cancer | Research

Biomarkers of lipid metabolism in gastric cancer: a case control study

Authors: Fangxuan Li, Jinli Dou, Lijuan Wei, Shixia Li, Juntian Liu

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

The aim of this study was to explore the correlation between biomarkers of lipid metabolism and gastric cancer.

Methods

1120 gastric cancer patients and 1134 health examiners enrolled in this study. The clinic data and serum lipid level, including Total cholesterol (TC), Triglyceride (TG), Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C), were collected.

Results

Serum TG and LDL-C levels in patients with gastric cancer were higher than those in the control group. HDL-C levels were lower than the control group (P < 0.05). HDL-C and LDL-C were significantly correlated with the risk of gastric cancer. Concentrating on clinicopathological features, increased TG was more frequently in male patients with distal gastric cancer, N0 stage and early TNM stage. Increased TC was more frequently in early T, N and TNM stage. Decreased HDL-C was more common in distal location and low-undifferentiated gastric cancer. LDL-C elevation was more common in distal gastric cancer and early T stage.

Conclusions

The serum lipid level of gastric cancer patients was higher than healthy controls. HDL-C and LDL-C abnormal correlated with gastric cancer risk. However, as the progresses of gastric cancer, poor patient intake, increased tumor consumption, and continuous declining in nutritional status, the levels of TC and TG gradually decreased in advanced gastric cancer.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed

Aleman JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ, Holt PR. Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology. 2014;146(2):357–73.CrossRefPubMed

Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.CrossRefPubMedPubMedCentral

Huan Yang J 1, Wang X, Wang W, Sun C, Tong J, Qiao FY, Christian C, Abnet. Weight change and all-cause and cause-specific mortality: a 25-year follow-up study. Chin Med J (Engl). 2024 Jan 29.online.

Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Impact of metabolically healthy obesity on the risk of incident gastric cancer: a population-based cohort study. BMC Endocr Disord. 2020;20(1):11.CrossRefPubMedPubMedCentral

Wei L, Zhang C, Zhang H, Wei X, Li S, Liu J, et al. A case-control study on the association between serum lipid level and the risk of breast cancer. Chin J Prev Med. 2016;50(12):1091–5.

Choi YJ, Lee DH, Han KD, Shin CM, Kim N. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol. 2018;33(11):1077–85.CrossRefPubMed

Zaleska M, Mozenska O, Bil J. Statins use and cancer: an update. Future Oncol. 2018;14(15):1497–509.CrossRefPubMed

10.

Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9(4):379–85.CrossRefPubMed

11.

Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, et al. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 2011;178(5):1953–64.CrossRefPubMedPubMedCentral

12.

Dong SR, Ju XL, Yang WZ. STAT5A reprograms fatty acid metabolism and promotes tumorigenesis of gastric cancer cells. Eur Rev Med Pharmacol Sci. 2019;23(19):8360–70.PubMed

13.

Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014;99(3):417–29.CrossRefPubMedPubMedCentral

14.

Lindkvist B, Almquist M, Bjorge T, Stocks T, Borena W, Johansen D, et al. Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the metabolic syndrome and Cancer Project (Me-Can). Cancer Causes Control. 2013;24(1):107–16.CrossRefPubMed

15.

Kim EH, Lee H, Chung H, Park JC, Shin SK, Lee SK, et al. Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer. Clin Res Hepatol Gastroenterol. 2014;38(3):372–8.CrossRefPubMed

16.

Kang R, Li P, Wang T, Li X, Wei Z, Zhang Z, et al. Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population. Sci Rep. 2016;6:19930.CrossRefPubMedPubMedCentral

17.

Matsubara D, Shoda K, Kubota T, Kosuga T, Konishi H, Shiozaki A, et al. Preoperative total cholesterol-lymphocyte score as a novel immunonutritional predictor of survival in gastric cancer. Langenbecks Arch Surg. 2019;404(6):743–52.CrossRefPubMed

18.

Nam SY, Park BJ, Nam JH, Kook MC. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019;90(3):448–56.CrossRefPubMed

19.

Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol. 2015;6:222.CrossRefPubMedPubMedCentral

20.

Xu S, Tan YFY. Association between blood lipid levels and risk of gastric cancer: a systematic review and meta-analysis. PLoS ONE. 2023;18(7):e0288111.CrossRefPubMedPubMedCentral

21.

Nam SY, Ryu KH, Park BJ, Park S. Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter. 2015;20(2):125–32.CrossRefPubMed

Title: Biomarkers of lipid metabolism in gastric cancer: a case control study
Authors: Fangxuan Li
Jinli Dou
Lijuan Wei
Shixia Li
Juntian Liu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Biomarkers
Dyslipidemia
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12230-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021

Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis

Epidemiological, clinical, and pathological characteristics of invasive breast cancer in Bedouin and Jewish women in southern Israel: a retrospective comparative study

Elucidating the role of EPPK1 in lung adenocarcinoma development

Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma

Impact of a one-year supervised physical activity program on long-term cancer-related fatigue and mediating effects of the gut microbiota in metastatic testicular cancer patients: protocol of the prospective multicentre, randomized controlled phase-III STARTER trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer